Givosiran
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Givosiran
- Pharmacist Assessment Report
- Givosiran: From Hepatic Porphyria to Early-Onset Familial Noncirrhotic Portal Hypertension
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Givosiran: From Hepatic Porphyria to Early-Onset Familial Noncirrhotic Portal Hypertension
One-Sentence Summary
Givosiran is a liver-targeted RNA interference drug, originally used to treat hepatic porphyria. The TxGNN model predicts it may be effective for early-onset familial noncirrhotic portal hypertension, but no clinical trials and no publications currently support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hepatic porphyria |
| Predicted New Indication | Early-onset familial noncirrhotic portal hypertension |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Givosiran is a GalNAc-conjugated small interfering RNA (siRNA). It is taken up by liver cells and silences the ALAS1 gene. This lowers the neurotoxic heme intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), which drive the attacks seen in acute hepatic porphyria.
The data compiled for this report do not establish a mechanistic link between ALAS1 suppression and noncirrhotic portal hypertension. That condition involves vascular and hepatoportal pathology, which heme-synthesis modulation is not known to address. The score of 1.0000 is identical to the scores of several other unrelated liver-vascular diseases (portal vein thrombosis, hepatoportal sclerosis, idiopathic copper-associated cirrhosis, hepatopulmonary syndrome). This suggests the model is picking up a generic “liver-related” association rather than a signal specific to this disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02506343 | GIVLAARI | Not listed | Not listed |
Safety Considerations
Drug Interactions: 87 interactions are recorded. The 20 reviewed include one major interaction and the rest moderate.
- Major: Eliglustat
- Moderate (examples):
- Aminoglycosides: vancomycin, kanamycin, neomycin, streptomycin
- Amphotericin B formulations
- Aminosalicylates: mesalazine, balsalazide, olsalazine, sulfasalazine
- Other: metoclopramide, naltrexone, exenatide, fenfluramine, alosetron, caffeine
Liver-related caution: Transaminase elevations have been seen with givosiran. This would be a concern in a patient with a diseased liver, such as one with portal hypertension or cirrhosis.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no trials or publications, and no plausible mechanism links ALAS1 silencing to noncirrhotic portal hypertension. The identical scores across unrelated diseases point to a non-specific output.
To proceed, the following is needed:
- A disease-specific mechanistic hypothesis connecting heme synthesis or ALAS1 to the pathology of portal hypertension
- Preclinical or early clinical evidence in this condition
- Review of the Health Canada package insert for warnings, contraindications, and hepatic safety in patients with liver disease
- Consider redirecting effort to the ALAD porphyria prediction, which has a stronger biological rationale. It would first need evidence that resolves the question of erythroid ALA production.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.